See more : The South Indian Bank Limited (SOUTHBANK.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Spyre Therapeutics, Inc. (SYRE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Spyre Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Addex Therapeutics Ltd (0QNV.L) Income Statement Analysis – Financial Results
- Senetas Corporation Limited (SEN.AX) Income Statement Analysis – Financial Results
- Australian Vanadium Limited (ATVVF) Income Statement Analysis – Financial Results
- Ancom Nylex Berhad (4758.KL) Income Statement Analysis – Financial Results
- Riley Exploration Permian, Inc. (REPX) Income Statement Analysis – Financial Results
Spyre Therapeutics, Inc. (SYRE)
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 886.00K | 2.33M | 18.74M | 0.00 | 0.00 | 3.89M | 5.21M | 4.63M | 6.09M | 0.00 |
| Cost of Revenue | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | 0.00 | 0.00 | 0.00 | 89.00K | 19.00K |
| Gross Profit | -78.00K | 365.00K | 16.74M | -1.62M | -901.00K | 3.89M | 5.21M | 4.63M | 6.00M | -19.00K |
| Gross Profit Ratio | -8.80% | 15.67% | 89.32% | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% | 98.54% | 0.00% |
| Research & Development | 89.50M | 58.58M | 57.07M | 59.64M | 64.60M | 36.72M | 22.82M | 18.14M | 11.45M | 6.83M |
| General & Administrative | 39.95M | 28.53M | 27.32M | 21.84M | 0.00 | 0.00 | 0.00 | 0.00 | 5.95M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 39.95M | 28.53M | 27.32M | 21.84M | 14.83M | 12.34M | 9.82M | 8.26M | 5.95M | 2.06M |
| Other Expenses | 113.74M | -7.00K | -122.00K | -5.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 79.43M | 49.06M | 32.63M | 26.40M | 17.40M | 8.89M |
| Cost & Expenses | 243.19M | 87.11M | 84.39M | 81.48M | 80.33M | 49.35M | 32.88M | 26.53M | 17.40M | 8.90M |
| Interest Income | 6.15M | 837.00K | 111.00K | 593.00K | 2.14M | 1.17M | 482.00K | 244.00K | 22.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 964.00K | 1.96M | 2.00M | 1.62M | 901.00K | 293.00K | 249.00K | 132.00K | 89.00K | 19.00K |
| EBITDA | -127.82M | -83.21M | -63.66M | -79.27M | -77.35M | -45.17M | -27.43M | -21.77M | -11.23M | -10.33M |
| EBITDA Ratio | -14,426.64% | -3,572.95% | -341.92% | 0.00% | 0.00% | -1,161.78% | -526.94% | -470.48% | -184.49% | 0.00% |
| Operating Income | -242.30M | -84.78M | -65.65M | -81.48M | -80.33M | -45.46M | -27.68M | -21.91M | -11.32M | -8.90M |
| Operating Income Ratio | -27,347.97% | -3,640.23% | -350.33% | 0.00% | 0.00% | -1,169.32% | -531.72% | -473.34% | -185.95% | 0.00% |
| Total Other Income/Expenses | -96.51M | 830.00K | -11.00K | 588.00K | 2.08M | 1.12M | 440.00K | 208.00K | 20.00K | -1.44M |
| Income Before Tax | -338.82M | -83.95M | -65.66M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Income Before Tax Ratio | -38,241.08% | -3,604.59% | -350.39% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| Income Tax Expense | -26.00K | -136.00K | 141.00K | -593.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -338.79M | -83.82M | -65.80M | -80.89M | -78.25M | -44.35M | -27.24M | -21.70M | -11.30M | -10.35M |
| Net Income Ratio | -38,238.15% | -3,598.75% | -351.14% | 0.00% | 0.00% | -1,140.64% | -523.27% | -468.84% | -185.62% | 0.00% |
| EPS | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.40 | -25.20 | -18.91 |
| EPS Diluted | -49.12 | -24.86 | -25.02 | -37.89 | -61.23 | -53.25 | -45.01 | -55.40 | -25.20 | -18.91 |
| Weighted Avg Shares Out | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
| Weighted Avg Shares Out (Dil) | 6.90M | 3.37M | 2.63M | 2.13M | 1.28M | 832.90K | 605.13K | 391.67K | 457.19K | 547.19K |
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Announces $180 Million Private Placement
Source: https://incomestatements.info
Category: Stock Reports